ELCC 2022 Archives - Medical Conferences

Home > Oncology > ELCC 2022

European Lung Cancer Congress
30 March–02 April 2022

Featured articles

ELCC 2022 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ELCC 2022

19 April, 2022 10:43

Furmonertinib outperforms gefitinib as first-line therapy in patients with EGFR-mutated NSCLC

Presented By

Dr Yuankai Shi, National Cancer Center, China

Trial

Phase 3, FURLONG

Conference

ELCC 2022

5 April, 2022 11:29

Immunotherapy delays deterioration in health-related quality of life in metastatic NSCLC

Presented By

Dr Edward Garon, David Geffen School of Medicine at UCLA, CA, USA

Trial

Phase 3, POSEIDON

Conference

ELCC 2022

1 April, 2022 10:54

Online First

Sintilimab plus chemotherapy improves OS in treatment-naïve stage III/IV non-squamous NSCLC

Presented By

Dr Yunpeng Yang, Sun Yat-sen University Cancer Center, China

Trial

Phase 3, ORIENT-11

Conference

ELCC 2022

5 April, 2022 11:35

M1 macrophages and upregulated gene expression predict complete pathological response to neoadjuvant chemoimmunotherapy

Presented By

Dr Marta Casarrubios, Hospital Puerta de Hierro-Majadahonda, Spain

Trial

Phase 2, NADIM

Conference

ELCC 2022

5 April, 2022 11:31

Furmonertinib outperforms gefitinib as first-line therapy in patients with EGFR-mutated NSCLC

Presented By

Dr Yuankai Shi, National Cancer Center, China

Trial

Phase 3, FURLONG

Conference

ELCC 2022

5 April, 2022 11:29

Decline in lung cancer mortality is almost exclusive to men

Presented By

Dr Philip Baum, Thoraxklinik Heidelberg, Germany

Conference

ELCC 2022

5 April, 2022 11:28

Peri-operative survival in bilobectomy is comparable with that of left pneumonectomy

Presented By

Dr Andrew Li, Yale School of Medicine, CT, USA

Conference

ELCC 2022

5 April, 2022 11:24

Positive benefit-risk profile for atezolizumab in PD-L1 TC ≥50% stage II-IIIA NSCLC

Presented By

Dr Enriqueta Felip, Vall d’Hebron University Hospital, Spain

Trial

Phase 3, IMpower010

Conference

ELCC 2022

4 April, 2022 12:50

Characteristics of long-term survivors in the CASPIAN trial

Presented By

Dr Niels Reinmuth, Asklepios Lung Clinic, Germany

Trial

Phase 3, CASPIAN

Conference

ELCC 2022

4 April, 2022 12:48

Durvalumab after sequential chemoradiotherapy safe in stage III, unresectable NSCLC

Presented By

Dr Marina Garassino, University of Chicago, IL, USA

Trial

Phase 2, PACIFIC-6

Conference

ELCC 2022

4 April, 2022 12:46

In concurrent chemoradiotherapy for stage III, unresectable NSCLC, proton-therapy bests photon therapy

Presented By

Dr Francesco Cortiula, Maastricht University Medical Center, the Netherlands

Conference

ELCC 2022

4 April, 2022 12:44

Non-pharmacological strategies for parental smoking cessation are effective, but not all

Presented By

Dr Jose Caduhada, Medical City Clinic-SM Valenzuela, Philippines

Conference

ELCC 2022

4 April, 2022 12:40

Immunotherapy delays deterioration in health-related quality of life in metastatic NSCLC

Presented By

Dr Edward Garon, David Geffen School of Medicine at UCLA, CA, USA

Trial

Phase 3, POSEIDON

Conference

ELCC 2022

1 April, 2022 10:54

Early-stage lung cancer diagnosis with liquid biopsy of peripheral blood cells

Presented By

Dr Andreas Thomsen, University of Freiburg, Germany

Conference

ELCC 2022

1 April, 2022 10:52

Physical function predicts long-term survival in early-stage NSCLC surgical patients

Presented By

Dr Cecilia Pompili, Leeds Institute of Medical Research, UK

Conference

ELCC 2022

1 April, 2022 10:51

Radiation dose on oesophagus predicts OS in SCLC patients treated with chemoradiotherapy

Presented By

Dr Bilal Tahir, University of Sheffield, UK

Conference

ELCC 2022

1 April, 2022 10:50

No long-term benefit of adding ipilimumab to pembrolizumab in metastatic NSCLC

Presented By

Dr Delvys Rodriguez-Abreu, Universidad de Las Palmas de Gran Canaria, Spain

Trial

Phase 3, KEYNOTE-598

Conference

ELCC 2022

1 April, 2022 10:48

Featured articles

CONTENTS

Online First